Once-a-Week GLP-1 RA: A Focus on CV Benefits

Introduction

Take This Event

Dr. Said Khader discusses the once-a-week GLP-1 RA option Dulaglutide with a focus on the cardiovascular benefits of the therapy for T2DM patients.

Objectives

To understand:
- Different cardiovascular trials design and patient population distribution
- The difference between primary and secondary CV protection
- Understand the results of recent CV trials for Dulaglutide and its implications on T2DM patients

See Registration Policies, Cancellations & Refunds